相关实验视频

Updated: May 14, 2025

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice

Published on: March 23, 2016

高效率的眼部输送来自大脑的神经营养因子和奥利戈米辛,用于玻璃眼的神经保护

Yuheng Cao^1,2, Xue Yin^1,3, Lanrong Wu¹

¹CAS Key Laboratory of Nano-Bio Interface, Suzhou Key Laboratory of Functional Molecular Imaging Technology, Division of Nanobiomedicine and i-Lab, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou, 215123, China.

Advanced materials (Deerfield Beach, Fla.)

|May 13, 2025

概括

一种新的纳米平台提供了寡素和来自大脑的神经营养因子 (BDNF),以保护视网膜质细胞 (RGCs) 在青光眼模型中. 这种双重疗法可以减少RGC损伤,并通过抑制ATP过度产生和增强神经保护来保护视力.

科学领域:

眼科医生眼科眼科
神经科学是一个神经科学.
生物技术是生物技术.

背景情况:

玻璃眼是一种神经退行性疾病,由于视网膜质细胞 (RGC) 亡,导致不可逆转的视力丧失.
目前的玻璃眼治疗缺乏直接的RGC神经保护,现有的神经营养因子输送方法面临着炎症和低效率等挑战.
对于针对RGCs的创新神经保护策略在青光眼治疗中至关重要.

研究的目的:

开发和评估一种新型纳米平台,用于联合提供ATP抑制剂和用于治疗青光眼的神经营养因子.
评估这种双输送系统在保护RGC和维护视神经功能的有效性.
通过解决RGC损伤和炎症反应,克服当前单疗法方法的局限性.

主要方法:

一个生物相容的纳米平台 (PBAE-PLGA-Oligomycin-pBDNF纳米颗粒,PPOB NP) 已被设计为联合交付.
该纳米平台在体内向Müller细胞输送了寡素 (ATP抑制剂) 和BDNF等离子体.
在慢性眼高血压大鼠模型中评估了PPOBNP的疗效.

主要成果:

PPOB NPs在米勒细胞中实现了前所未有的64.26%的转化效率.
奥利戈美辛抑制了穆勒细胞过度活化和过度的ATP产生,在眼内压力升高时减轻RGC损伤.
联合交付协同增强了BDNF表达,导致强大的RGC保护和视神经功能保护.

结论:

PPOB NP纳米平台展示了高生物相容性和高效的基因传递,用于双重功能玻璃眼治疗.
这种方法通过抑制有害的ATP产生和增强神经营养支持,有效地保护RGC.
PPOB NPs代表了对青光眼和其他眼部神经退行性疾病的有前途的治疗策略.

关键词:

穆勒细胞是什么?基因治疗的基因疗法玻璃眼 glaucoma 玻璃眼玻璃眼玻璃眼玻璃眼神经保护神经保护视网膜的质细胞细胞.

更多相关视频

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye

Published on: March 30, 2020

Methods for Experimental Manipulations after Optic Nerve Transection in the Mammalian CNS

Methods for Experimental Manipulations after Optic Nerve Transection in the Mammalian CNS

Published on: May 12, 2011

相关概念视频

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Glaucoma: Overview

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...

Angle Closure Glaucoma: Treatment

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...